Concentra Group Holdings Parent, Inc. (CON)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$34.47-0.12%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Concentra grows revenue about 7% a year, with recent 13.7% growth. Profit margins stay near 20%. Free cash flow is solid at about $225 million. Dividends remain steady, showing stable capital return.
Revenue growth could slow below 7%. Profit margins might compress from 20%. Free cash flow could weaken, pressuring dividends and capital allocation.
The price is about 14% above our fair value near $28. Analysts expect roughly 7% revenue growth. Our view aligns with these expectations but sees limited upside beyond that.
Breaks if: Dividend per share falls below $0.06 in next 4 quarters
Continue paying quarterly cash dividends at $0.0625 per share, subject to Board discretion.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a multi-year view on a business that is currently showing strong financial performance but has a volatile management track record. The investment thesis remains intact as the company is focused on revenue growth and profitability improvements.
The market seems to have priced in a low level of execution quality, indicating some fragility. The valuation is considered cheap compared to peers, with a slight expectations gap suggesting that investors are not overly optimistic.
Management is on track to grow revenue and increase operating income, with recent results showing strong growth. However, there is a low probability of missing expectations, although past performance has shown volatility.
The thesis hinges on maintaining momentum in the healthcare sector and avoiding any negative guidance cuts. Additionally, the performance of sector leaders and broader economic indicators, like job reports, will be critical.
The most important moves since the prior daily snapshot.
Signal changed from 'favorable' to 'mild_favorable'.
Yes, our read has strengthened. The latest earnings beat supports this view. S&P upgraded Concentra's rating to BB, indicating improved financial stability. There are no new threats affecting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 4 of last 4 quarters. The Board consistently declared quarterly dividends of $0.0625 per share from 2025-Q3 through 2026-Q2. Dividend payments have been maintained steadily, reflecting management's commitment to consistent capital return.
“On August 5, 2026, the Board declared a cash dividend of $0.0625 per share payable August 28, 2026.”
“On May 5, 2026, the Board declared a cash dividend of $0.0625 per share payable June 9, 2026.”
“On February 25, 2026, the Board declared a cash dividend of $0.0625 per share payable March 19, 2026.”
“Dividend declared at $0.0625 per share for prior quarters.”
Breaks if: Free cash flow falls below $200 million in FY26
Breaks if: Operating margin falls below 18% in FY26
Enhance operating income through improved efficiency and cost management.
Breaks if: YoY revenue growth falls below 7% in FY26
Continue to increase revenue through organic growth, acquisitions, and opening new centers.
Stated as a priority in 4 of last 4 quarters. Revenue grew from $500.8 million in 2026-Q1 to $606.0 million in 2026-Q2 (+10.0% YoY). Full-year 2026 revenue guidance was raised from $2.275-$2.375 billion in Q1 to $2.325-$2.375 billion in Q2, indicating management is delivering on growth.
“The quarter included revenue growth of 10.0%... Concentra raised its financial guidance for 2026: Revenue in the range of $2.325 billion to $2.375 billion.”
“Revenue of $569.6 million, an increase of 13.7% from $500.8 million in Q1 2025... raised guidance for full year 2026 revenue to $2.275 billion to $2.375 billion.”
“Revenue of $539.1 million, an increase of 15.9% from $465.0 million in Q4 2024... For full year 2026, revenue guidance is $2.25 billion to $2.35 billion.”
“Raised financial guidance for 2025 revenue to $2.145 billion to $2.160 billion.”
Over the next 1 to 3 years, CON's performance will depend on its ability to navigate sector dynamics and maintain growth. Not investment advice.